Daily non-political popular news in brief.

Modeling lung cancer

In a new report in the February 15 issue of G&D, Dr. Martin McMahon and colleagues present a novel mouse model of non-small cell lung cancer, which will serve as a useful tool to test the efficacy of novel chemotherapeutic drug therapies in the early stages of lung tumorigenesis. Their paper provides evidence to support the use of a relatively new class of drugs, called MEK inhibitors, for lung cancer patients whose tumors contain mutations in the BRaf gene.

Read more »

Keywords: modeling, lung, cancer

« Previous | Next »

Similar news on "Modeling lung cancer":

1. Simple diagnostic test detects genetic signs of lung cancer in a patient's sputum
   01-18-2007 · EurekAlert!
   DNA coughed up along with phlegm could point to lung cancer, say researchers at the University of Maryland School of Medicine who are developing an inexpensive and non-invasive gene probe to help diagnose early stage lung cancer in current and former smokers.
   Similar news · Read more »
   
2. Radiation preferred over surgery for patients with some stages of lung cancer
   03-20-2007 · EurekAlert!
   After an initial chemotherapy treatment, radiation may be a better choice than surgery for patients with stage IIIA non-small-cell lung cancer, according to a randomized controlled trial published in the March 21 Journal of the National Cancer Institute. The authors suggest that a combination of chemotherapy and radiation should be the preferred treatment option for these patients.
   Similar news · Read more »
   
3. FDG-PET imaging clearly predicts lung cancer patients' response to chemotherapy
   05-09-2007 · EurekAlert!
   An earlier indication of whether chemotherapy benefits non-small cell lung cancer patients -- provided by positron emission tomography (PET) imaging -- can guide doctors in offering them better care, according to researchers in the May Journal of Nuclear Medicine.
   Similar news · Read more »
   
4. Gene variations point to why lung cancer drugs work better in Japanese vs. US patients
   06-02-2007 · EurekAlert!
   Recent clinical trials revealed that Japanese lung cancer patients survived longer and had a higher rate of side effects than US patients taking the same two drugs, paclitaxel and carboplatin. Now a new study by the Southwest Oncology Group uncovers genetic differences that may explain why. The results, embargoed for release 8:30 a.m. ET Saturday, June 2, are being highlighted at the American Society of Clinical Oncology annual meeting.
   Similar news · Read more »
   
5. Knee arthritis link to lung cancer
   09-03-2007 · EurekAlert!
   Arthritis of the knee may be the first sign of a type of lung cancer that is hard to treat in heavy smokers, suggests research published ahead of print in the Annals of the Rheumatic Diseases. The researchers reviewed the case notes of all patients with rheumatic disorders, diagnosed at one tertiary referral centre over six years.
   Similar news · Read more »
   
6. Studies suggest key correlation between lung cancer subtype and treatment outcomes
   09-26-2007 · EurekAlert!
   In clinical research, patients with advanced non-small cell lung cancer that are classified as having a non-squamous histology achieve statistically significant higher survival when treated in the second-line setting with ALIMTA (pemetrexed for injection) when compared to histologically-similar patients treated with docetaxel.
   Similar news · Read more »
   
7. JCI table of contents: Nov. 15, 2007
   11-15-2007 · EurekAlert!
   This release contains summaries, links to PDFs and contact information for the following newsworthy papers to be published online, Nov. 15, 2007, in the JCI, including: CD200 stifles antitumor immunity; ClC-1 helps mice get a move on; A gut reaction to infection; Sensing bacteria in the gut keeps inflammation at bay; Uncovering the mechanisms underlying lung scarring; and Breast cancer SK(i)P(s)2 the beat.
   Similar news · Read more »
   
8. Drug that chokes off tumor blood vessels offers new hope to lung cancer patients
   12-13-2006 · EurekAlert!
   Patients suffering from the most common type of lung cancer experienced a 20-percent improvement in overall survival in a national clinical trial of a drug that chokes off the blood vessels nourishing tumors, a multicenter study has found.
   Similar news · Read more »
   
9. Minimally invasive lung cancer surgery can improve chemotherapy outcomes
   04-09-2007 · EurekAlert!
   Patients who undergo a minimally invasive lung cancer surgery called thoracoscopic lobectomy may derive more benefit from the chemotherapy that follows, according to Duke University Medical Center researchers. These patients also have shorter hospital stays and accelerated recovery time compared with patients who have their tumors removed using the traditional surgical approach that involves opening the chest.
   Similar news · Read more »
   
10. Targeted, oral agent Enzastaurin shows favorable results
    06-02-2007 · EurekAlert!
    Enzastaurin, an investigational targeted, oral agent under development by Eli Lilly and Company, showed encouraging results in treating patients with late-stage non-small cell lung cancer (NSCLC), according to data presented today at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO).
    Similar news · Read more »